# OnCo record lenalidomide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lenalidomide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lenalidomide" ;
  schema:name "Lenalidomide"@en ;
  schema:description "Lenalidomide is a thalidomide descendant that glues the proteins IKZF1 and IKZF3 to cereblon so the cell destroys them, killing plasma cells and rousing T cells. It is the backbone of myeloma treatment and maintenance, also used in mantle cell and follicular lymphoma, and generic since 2022."@en ;
  schema:url <https://onco.cc/drugs/lenalidomide/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Lenalidomide> ;
  owl:sameAs <http://www.wikidata.org/entity/Q425681> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lenalidomide> ;
  onco:status "approved" ;
  onco:modality "Immunomodulatory drug (cereblon E3 ligase modulator)" ;
  schema:alternateName "Revlimid" ;
  onco:approval "US 2005: Transfusion-dependent anaemia in low-risk MDS with del(5q)", "US 2006: Relapsed myeloma with dexamethasone", "US 2015: Newly diagnosed myeloma with dexamethasone", "US 2017: Maintenance after autologous transplant" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/myeloma-transplant-ineligible/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/ikzf1/>, <https://onco.cc/targets/ikzf3/> ;
  onco:companies <https://onco.cc/companies/bms/>, <https://onco.cc/companies/natco/> ;
  onco:trials <https://onco.cc/trials/nct05438043/>, <https://onco.cc/trials/nct04712097/>, <https://onco.cc/trials/nct05429268/>, <https://onco.cc/trials/nct06149286/>, <https://onco.cc/trials/nct05623020/>, <https://onco.cc/trials/nct05827016/>, <https://onco.cc/trials/nct06508658/>, <https://onco.cc/trials/nct06191744/>, <https://onco.cc/trials/nct06911502/>, <https://onco.cc/trials/nct04224493/>, <https://onco.cc/trials/nct07095452/>, <https://onco.cc/trials/nct06679101/>, <https://onco.cc/trials/nct04680052/>, <https://onco.cc/trials/nct05317416/>, <https://onco.cc/trials/nct05552222/>, <https://onco.cc/trials/nct06045806/>, <https://onco.cc/trials/nct04404283/>, <https://onco.cc/trials/nct05100862/>, <https://onco.cc/trials/nct05888493/>, <https://onco.cc/trials/nct05409066/>, <https://onco.cc/trials/nct05371093/>, <https://onco.cc/trials/nct05222555/>, <https://onco.cc/trials/nct02343042/>, <https://onco.cc/trials/nct04663347/>, <https://onco.cc/trials/nct04133636/>, <https://onco.cc/trials/nct05583617/>, <https://onco.cc/trials/nct07189065/>, <https://onco.cc/trials/nct06577025/>, <https://onco.cc/trials/nct05950165/>, <https://onco.cc/trials/nct06087653/>, <https://onco.cc/trials/nct02180711/>, <https://onco.cc/trials/nct07150091/>, <https://onco.cc/trials/nct04782687/>, <https://onco.cc/trials/nct04246086/>, <https://onco.cc/trials/nct06892522/>, <https://onco.cc/trials/nct05283720/>, <https://onco.cc/trials/nct04669171/>, <https://onco.cc/trials/nct07018050/>, <https://onco.cc/trials/nct04270409/>, <https://onco.cc/trials/nct06084936/>, <https://onco.cc/trials/nct06082102/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-augment-lenalidomide-rituximab-leonard-jco-2019/>, <https://onco.cc/key-papers/paper-ifm-2009-attal-nejm-2017/> .